Oculis Completes $100 Million Share Offering
ZUG, Switzerland — Oculis Holding AG (NASDAQ: OCS) has successfully priced an underwritten offering of 5,000,000 ordinary shares. The shares were priced at $20.00 each, generating total gross proceeds of approximately $100 million, before any deductions associated with underwriting and offering expenses.
Details of the Offering
This oversubscribed offering is slated to close soon, pending the usual closing conditions. The newly issued shares will be drawn from the company’s existing capital band, raising the total authorized number of shares up to 53,943,700 as outlined in Oculis' Articles of Association.
Strategic Use of Proceeds
Oculis plans to utilize the net proceeds from this offering to accelerate its clinical development endeavors, notably focusing on its promising neuroprotective candidate, Privosegtor (OCS-05). This candidate is envisioned to address acute optic neuritis and has potential applications in other neuro-ophthalmic conditions. Additionally, the funds will support ongoing working capital needs and other general corporate purposes.
Management of the Offering
Key players in this offering include BofA Securities and Leerink Partners, both serving as joint bookrunning managers. Pareto Securities has joined as the lead manager, while Arctica Finance offers financial advisory services to ensure a smooth process.
Regulatory Compliance
The offering adheres to a prior registration statement filed with the U.S. Securities and Exchange Commission (SEC). The shares are being privately offered in the United States through a detailed prospectus supplement, ensuring compliance with relevant securities regulations.
Oculis: A Leader in Eye Care Innovation
Oculis is renowned for its dedication to revolutionizing eye care through innovative biopharmaceutical solutions. With a robust pipeline including OCS-01 for diabetic macular edema and Licaminlimab (OCS-02) for dry eye disease, Oculis is poised to significantly impact the landscape of ophthalmic treatment. The company’s operations span across Switzerland, the U.S., and Iceland, supported by a proficient management team well-versed in healthcare investment.
Future Prospects
As Oculis continues to navigate its clinical trials and product development, the infusion of capital from this share offering stands to boost growth prospects significantly. The company’s focus on unmet medical needs positions it as a frontrunner in the biopharmaceutical sector, particularly in its commitment to enhancing vision and eye health.
Oculis Contact Information
For inquiries related to this press release or to learn more about Oculis' offerings, stakeholders can reach out to Ms. Sylvia Cheung, CFO, via email at sylvia.cheung@oculis.com.
Frequently Asked Questions
What is the goal of Oculis' $100 million offering?
The proceeds aim to accelerate clinical development, particularly for the drug Privosegtor (OCS-05), and support general corporate needs.
Who is managing the offering?
The offering is managed by BofA Securities and Leerink Partners, with Pareto Securities as the lead manager.
How many shares are included in the offering?
Oculis has priced an offering of 5,000,000 ordinary shares at $20.00 each.
What is the significance of the capital band?
The capital band allows Oculis to issue new shares while maintaining compliance with its Articles of Association.
Where is Oculis headquartered?
Oculis is headquartered in Switzerland but has operations in both the U.S. and Iceland, supporting its global reach in innovative eye care solutions.
